Protalix BioTherapeutics Inc. (AMEX:PLX) went down by -0.68% from its latest closing price compared to the recent 1-year high of $7.02. The company’s stock price has collected 5.51% of gains in the last five trading sessions. Press Release reported 2 hours ago that Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
Is It Worth Investing in Protalix BioTherapeutics Inc. (AMEX :PLX) Right Now?
Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Protalix BioTherapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $11.00. PLX currently public float of 19.48M and currently shorts hold a 2.60% ratio of that float. Today, the average trading volume of PLX was 552.03K shares.
PLX’s Market Performance
PLX stocks went up by 5.51% for the week, with a monthly jump of 12.27% and a quarterly performance of 39.35%, while its annual performance rate touched 33.59%. The volatility ratio for the week stands at 7.19% while the volatility levels for the past 30 days are set at 7.84% for Protalix BioTherapeutics Inc.. The simple moving average for the period of the last 20 days is 4.52% for PLX stocks with a simple moving average of 37.20% for the last 200 days.
Analysts’ Opinion of PLX
Many brokerage firms have already submitted their reports for PLX stocks, with H.C. Wainwright repeating the rating for PLX by listing it as a “Buy.” The predicted price for PLX in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on June 08th of the previous year 2020.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see PLX reach a price target of $5, previously predicting the price at $4. The rating they have provided for PLX stocks is “Buy” according to the report published on April 17th, 2017.
Rodman & Renshaw gave a rating of “Buy” to PLX, setting the target price at $3.50 in the report published on April 04th of the previous year.
PLX Trading at 21.51% from the 50-Day Moving Average
After a stumble in the market that brought PLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.85% of loss for the given period.
Volatility was left at 7.84%, however, over the last 30 days, the volatility rate increased by 7.19%, as shares surge +14.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +38.48% upper at present.
During the last 5 trading sessions, PLX rose by +7.87%, which changed the moving average for the period of 200-days by +65.82% in comparison to the 20-day moving average, which settled at $4.95. In addition, Protalix BioTherapeutics Inc. saw 42.42% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at PLX starting from Schwartz Aharon, who purchase 64,000 shares at the price of $2.43 back on Apr 07. After this action, Schwartz Aharon now owns 64,000 shares of Protalix BioTherapeutics Inc., valued at $155,264 using the latest closing price.
Stock Fundamentals for PLX
Current profitability levels for the company are sitting at:
- -19.74 for the present operating margin
- +80.08 for the gross margin
The net margin for Protalix BioTherapeutics Inc. stands at -33.42.
When we switch over and look at the enterprise to sales, we see a ratio of 1.66, with the company’s debt to enterprise value settled at 0.67. The receivables turnover for the company is 11.60 and the total asset turnover is 1.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.81.